Miyo Masaaki, Kato Takeshi, Miyake Yasuhiro, Kato Aya, Sakamoto Takuya, Doi Takashi, Hoshi Minako, Makari Yoichi, Oshima Satoshi, Iijima Shouhei, Kurokawa Eiji, Kikkawa Nobuteru
Department of Surgery, Minoh City Hospital.
Gan To Kagaku Ryoho. 2009 Nov;36(12):2160-2.
A man in his fifties with rectal cancer underwent low anterior resection in another Hospital in January 2006. He was finally diagnosed with Stage III a (pA, pN1, H0, P0). The patient who had postoperative complication such as ruptured suture left the hospital in May 2006, when he was detected with multiple liver metastases and was referred to our hospital for systemic chemotherapy. Systemic chemotherapy with mFOLFOX6 was performed from May 2006. Grade 3 diarrhea and grade 2 peripheral neuropathy, nausea and vomiting were observed. After 6 courses of mFOLFOX6, MRI revealed metastasis had been disappeared and levels of CEA and CA19-9 were decreased below normal. The treatment has been discontinued. Recurrence was not observed for 30 months.
一名50多岁的直肠癌男性患者于2006年1月在另一家医院接受了低位前切除术。他最终被诊断为III a期(pA,pN1,H0,P0)。该患者术后出现缝线破裂等并发症,于2006年5月出院,当时检测到多发肝转移,遂转诊至我院进行全身化疗。自2006年5月起进行mFOLFOX6全身化疗。观察到3级腹泻、2级周围神经病变、恶心和呕吐。6个疗程的mFOLFOX6治疗后,MRI显示转移灶消失,CEA和CA19-9水平降至正常以下。治疗已停止。30个月未观察到复发。